#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss
Peter Attia
Jun 29, 2026
Episode description
View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this "Ask Me Anything" (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may be more important than body composition metrics alone. He also explores how GLP-1–based therapies affect different fat depots throughout the body, identifies who may be most vulnerable to muscle loss, and outlines practical strategies for preserving muscle and bone health while using these medications. Finally, Peter reviews early insights into retatrutide, a next-generation weight-loss therapy, including what current evidence suggests about its effects on weight loss and muscle mass.
If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #86 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
We discuss:
The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45];
Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45];
How newer research has changed the understanding of lean mass loss on GLP-1 receptor agonists and why DEXA measurements can misrepresent muscle loss [6:
Mindsip insights from this episode:
Reevaluate DEXA scans for accurate lean mass assessment
The measurement of lean mass loss on a DEXA scan can be misleading when assessing the true impact of weight loss from GLP-1 agonists.
Anticipate retatrutide's FDA approval for weight and muscle mass benefits
A new drug called retatrutide is already making its way through development and will soon be an FDA-approved option with its own unique effects on weight and muscle mass.
Embrace third generation GLP-1s for significant effectiveness
The third generation of GLP-1 agonists, like semaglutide, represented a 'step function change' in effectiveness compared to earlier versions that were found to be 'relatively uninspiring'.
Counsel patients on nutrition and exercise to improve outcomes
The degree of muscle loss on these drugs is not fixed, as outcomes can be significantly changed by counseling patients on their nutrition and exercise.
Avoid over-interpreting clinical trial data for personalized health insights
You must be careful not to over-interpret the averaged, homogenized data from clinical trials, as they don't reflect how individual patients were counseled on diet and exercise.
Monitor muscle loss ratio with GLP-1 agonists for effective weight management
Early observations of patients on GLP-1 agonists showed an almost one-to-one ratio of lean mass loss to fat loss, which is a much higher rate of muscle loss than seen with other weight loss methods.
More from
Peter Attia
#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.
Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast)
#397 ‒ Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, and emerging treatments | Renato Tomioka, M.D., Ph.D.
#396 ‒ Breast cancer screening: understanding risk, deciding when to start and how often to screen, and choosing the right imaging strategy
#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.
